All Articles

A new virtual exhibit showcases public art from all 50 states, democratizing culture for America's 250th. What does this mean for the art industry?

As AI agent pilots face a 95% failure rate due to soaring costs, Neurometric AI emerges with a $4M funding round and a new discipline: automated token engineering.

Americans spend hundreds annually on toilet paper, a product with a vast hidden environmental cost. A simple tech upgrade offers a payback in under a year.

Tarik Freitekh's new memoir details a life built on a phantom fortune, ending in prison. It's a stark lesson in the real cost of a fabricated reputation.

A former congressional candidate launches a podcast aiming to counter outrage. We analyze the strategic pivot and market viability of this new media venture.

A new AI platform for dental offices, Veo, is skipping the automation hype to focus on something radical: keeping humans in control. Is this the future?

Koppers reports historic safety and emissions lows in its 2025 CSR, but the real story is its refreshed 2030 strategy—a plan for resilience and value.

Greenland Mines charts a bold path for its Skaergaard project, but can it navigate the treacherous terrain of Arctic mining and financial instability?

Private equity giant Onex Partners acquires Canada's top fractional jet operator, AirSprint, in a strategic move to dominate the booming private aviation market.

As the GLP-1 market booms, Vivani Medical's new semaglutide implant promises a 'set-and-forget' solution to the adherence crisis plaguing weight-loss drugs.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Automotive tech giant Visteon announced a massive share repurchase, delighting Wall Street. But in an industry demanding relentless innovation, is this the best use of capital?

Bluespring Wealth's acquisition of Element Wealth Advisors highlights a key industry trend: indie firms are seeking scale and tech to fuel client-first growth.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

A new partnership promises a less painful way to deliver cancer immunotherapy. We dive into the tech, the market, and why this is a key strategic play.

Eightco Holdings offers a single stock for exposure to the future's giants. Is its concentrated bet on AI, crypto, and creators a stroke of genius?

An institutional investor just paid a 25% premium for VCI Global stock. We go beyond the headline to unpack the AI platform that commanded this confidence.

RenX Enterprises pushes forward with its advanced soil facility, but a key mill is delayed, highlighting the clash between green-tech vision and reality.

A Memphis family office, born from retail, is investing in AI's foundational layer. It's a sign of a larger shift as patient capital chases a new prize.